Results 221 to 230 of about 41,691 (265)

The RANKL Pathway and Denosumab

Rheumatic Disease Clinics of North America, 2011
Denosumab (Prolia) is a fully human monoclonal antibody directed against receptor activator of nuclear factor-κB ligand (RANKL), which interferes with the formation, activation, and survival of osteoclasts. It was approved by the Food and Drug Administration in June 2010 as a new treatment for postmenopausal osteoporosis in women who are at high risk ...
openaire   +2 more sources

RANKL as a target for the treatment of osteoporosis

Journal of Bone and Mineral Metabolism, 2020
Osteoporosis is characterized by compromised bone strength, predisposing to an increased risk of fracture. Because bone is constantly remodeled, and bone mass and structure are determined by the balance between bone resorption and bone formation, it is important to maintain normal bone turnover.
Toshio, Matsumoto, Itsuro, Endo
openaire   +2 more sources

RANKL and RANK in Cancer Therapy

Physiology, 2023
Receptor activator of nuclear factor-κB (RANK) and its ligand (RANKL) are key regulators of mammalian physiology such as bone metabolism, immune tolerance and antitumor immunity, and mammary gland biology. Here, we explore the multiple functions of RANKL/RANK in physiology and pathophysiology and discuss underlying principles and strategies to ...
Masahiro Onji, Josef M. Penninger
openaire   +2 more sources

The immune system, bone and RANKL

Archives of Biochemistry and Biophysics, 2014
Bone and immune systems are tightly linked. In the past years, many molecules originally believed to belong to the immune system were found to function in bone cells. It is now evident that the two systems are coregulated by many shared cytokines and signaling molecules.
Matteo M, Guerrini, Hiroshi, Takayanagi
openaire   +2 more sources

RANKL-independent modulation of osteoclastogenesis

Journal of Oral Biosciences, 2019
Osteoclasts are functional cells required for bone resorption. They are derived from hematopoietic precursors and undergo a series of differentiation and fusion steps in response to various humoral factors. Depending on the importance in osteoclastogenesis, the pathways for the differentiation of hematopoietic precursors to mature osteoclasts can be ...
Wei, Feng, Jie, Guo, Minqi, Li
openaire   +2 more sources

The RANKL/RANK/OPG pathway

Current Osteoporosis Reports, 2007
Understanding of osteoclast formation and activation has advanced considerably since the discovery of the RANKL/RANK/OPG system in the mid 1990s. Osteoblasts and stromal stem cells express receptor activator of NF-jB ligand (RANKL), which binds to its receptor, RANK, on the surface of osteoclasts and their precursors. This regulates the differentiation
Brendan F, Boyce, Lianping, Xing
openaire   +2 more sources

[RANKL vaccination].

Nihon rinsho. Japanese journal of clinical medicine, 2005
A therapeutic vaccine approach, targeting RANKL, can be used to inhibit bone destruction in pathological bone loss conditions such as osteoporosis, rheumatoid arthritis and bone metastasis. Compared to other therapeutic recombinant protein against pathological antigen such as monoclonal antibodies, soluble receptor or other antagonists, a vaccine needs
Takuo, Juji, Sakae, Tanaka
openaire   +1 more source

Denosumab: Anti-RANKL antibody

Current Osteoporosis Reports, 2009
Denosumab (anti-receptor activator of nuclear factor-kappaB ligand antibody) is a novel agent, a fully human monoclonal antibody that inhibits osteoclastic-medicated bone resorption by binding to osteoblast-produced RANKL. By reducing RANKL binding to the osteoclast receptor RANK, bone resorption and turnover decrease.
openaire   +2 more sources

RANKL

2011
  +4 more sources

Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption

Cell, 2021
Michelle M Mcdonald, Weng Hua Khoo, Danyal Butt   +2 more
exaly